The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical symptoms of these disorders. These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been suggested that the persisting therapeutic effects of psychedelics are attributable to a similar biological mechanism (39, 40).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [39]
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“5 mg per kg), and this effect was sustained for at least 72 hour”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Dissociative anaesthetics mimic the positive and the negative symptoms (social withdrawal and apathy) of schizophrenia through antagonism at NMDA ( N -methyl- D -aspartate) glutamate receptor”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Systemic administration of non-competitive NMDA antagonists, such as ketamine, PCP and MK-801 (also known as dizocilpine), in rats markedly increases glutamate release in the mPF”
BackgroundDavis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“and was rated as among the most personally meaningful experience”
Background(1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
(2009) · Elsevier eBooks · doi:10.1016/c2009-1-03742-3 · Cited by 1,308
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“These effects are probably due to a blockade of NMDA receptors on GABA (γ-aminobutyric acid)-ergic interneuron”
Background
Research works printed but not linked: 6
- Hofmann, A. in Chemical Constitution and Pharmacodynamic Actions (ed. Burger, A.) 169–235 (M.Dekker, New York, 1968).
- Dittrich, A. in 50 Years of LSD. Current Status and Perspectives of Hallucinogens (eds Pletscher, A. & Ladewig, D.) 101–118 (Parthenon, New York, 1994).
- Hoffer, A. in The Uses and Implications of Hallucinogenic Drugs (eds Aaronson, B. & Osmond, H.) 357–366 (Hogarth Press, London, 1970).
- Leuner, H. in 50 Years of LSD: Current Status and Perspectives of Hallucinogen Research (eds Pletscher, A. & Ladewig, D.) 175–189 (Parthenon, New York, 1994).
- Crocket, R., Sandison, R. A. & Walk, A. in Proc. R. Med–Psychol. Assoc. (Lewis & Co., London, 1963).
- Leuner H. in Ethnopsychotherapie (eds Dittrich, A. & Scharfetter, C.) 151–161 (Enke, Stuttgard, 1987)
Cited by
Items 701–721 of 721
Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms
Hummel, H. M., Obrochta, A. N., Kerr, D. C. R., & Cservenka, A. (2026) · Journal of Drug Issues · doi:10.1177/00220426261466154
How Do Drugs Work in the Brain?
Kleiman, M. A. R., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.005.0013
Wawrzczak‐Bargieła, A., Jelonek-Kozioł, M., Kumorek, W., Bilecki, W., & Maćkowiak, M. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07132-6
Jones, G. H., Gilbert, J. R., Johnston, J. N., Akula, N., Schulmann, A., Arakelian, M. H., Peng, S., Yuan, P., Winful, E. A., Yavi, M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03777-z
Molecules, meaning, and physiology: disentangling the active ingredients of psychedelic therapeutics
Kuypers, K. P. C. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1892474
“Activation of 5-HT2A receptors on deep-layer pyramidal neurons increases neuronal excitability and disrupts the stability of intrinsic networks, including the default mode, salience, and frontoparietal control networks (Vollenweider and Kometer, 2010; Banushi and Polito, 2023).”
O'Shea, A., Mason, N. L., Briedé, J. J., Schreiber, R., Verheijen, M. C. T., Krauskopf, J., & Ramaekers, J. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.04.742737
“Moreover, psychedelics have been associated with alterations in glutamatergic signalling, which are thought to contribute to sustained neuroplasticity and reductions in depressive symptoms (Vollenweider and Kometer, 2010).”
Ross, B. M. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00517
Psilocibina e neuroplasticidade: novas perspectivas terapêuticas para depressão resistente
Castro, L. A., Júnior, A. L. A. S., Simões, G. G. C., de Souza, V. R. S., Pereira, L. L. M. D., Lacerda, A. L. D. S., & da Silva, C. L. (2026) · Vértices · doi:10.19180/1809-2667.v28n22026.23658
Fletcher, K., Freestone, J., Ezard, N., Knock, E., & Siefried, K. J. (2026) · Current Addiction Reports · doi:10.1007/s40429-026-00783-7
HORMONAL MODULATION OF PSILOCYBIN RESPONSIVITY ACROSS THE FEMALE REPRODUCTIVE LIFESPAN
Pawłucka, K., Pawlucka, A., Kadłuczka, J., Hejduk, M., Grzymek, M., Bury, J., Kraska, K., Potoniec, J., Kępa, W., Sobek, A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6195
Pour une philosophie des psychédéliques
Léger, P. (2026) · Psychotropes · doi:10.3917/psyt.323.0059
Orallo, D. E., Parise, A. R., Echarte, S. M., Iurlina, M. O., & Ramírez, C. L. (2026) · Studies in natural products chemistry · doi:10.1016/b978-0-443-51072-4.00016-8
Embodied Transformation: Psychedelic Therapy Through the Lens of Merleau-Ponty’s Phenomenology
Ritschel, Z., & Wagoner, B. (2026) · Integrative Psychological and Behavioral Science · doi:10.1007/s12124-026-10029-w
“The first argues that such experiences are merely epiphenomenal, meaning that they are secondary to underlying neurological processes like increased neuroplasticity (Vollenweider & Kometer, 2010).”
Niedernhuber, M., Suay, D., Lenggenhager, B., Müller, M., Scheidegger, M., Dornbierer, D., & Aicher, H. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261481062
Souza, E. V., Floresta, L. R. D. S., Andrade, A. R. D. S., de Amorim, P. L., Silva, D. D. M. E., Silva, A. C. A., & Oliveira, J. M. (2026) · Phytomedicine Plus · doi:10.1016/j.phyplu.2026.101046
Stress history determines psilocybin’s effects on fear extinction in male adolescent rats
Virakorn, E. A., Baker, K., Everett, N. A., & Richardson, R. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100833
Maekawa, R. M., Guerra, L. T. L., Villanova, B., de Paula, C. C., Vicentini, A. B., Rodrigues, L. S., Reis, J. A. S., Rossi, G. N., Bouso, J. C., Hallak, J. E. C., et al. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002264
Żełabowski, K., Wieczorek, T., & Hamed, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1852799
“Vollenweider and Kometer set this finding within a wider neurobiological context, framing 5-HT 2A agonism and the resulting increase in cortical glutamatergic activity as the primary pharmacological mechanism of the psychedelic state (Vollenweider and Kometer, 2010).”
Morena, D., Lippi, M., Biso, L., Lucci, F., Turillazzi, E., Fineschi, V., & Scognamiglio, P. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01599-z
“Most published cases of SS have occurred in the context of polypharmacy involving other serotonergic agents or recreational use, where drug composition, dosage, and co-exposures are often poorly characterized [52–57].”
Cubała, W. J. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2744754
Flores, A., Carrasco, I. L. L., Lozano-Espinosa, M., Soriano-Agueda, L. A., Gómez-Castro, C. Z., & Franco‐Pérez, M. (2026) · Research Square · doi:10.21203/rs.3.rs-11502694/v1
Metadata
- Authors
- Vollenweider, F. X., & Kometer, M.
- Affiliations
- University of Zurich (CH)
- University Hospital Zurich (CH)
- Corresponding author
- Vollenweider, Franz X.
- Venue
- Nature Reviews Neuroscience
- Published
- 2010-08-18
- Volume
- 11
- Issue
- 9
- Pages
- 642-651
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2068751924
- Semantic Scholar
- d95a57f4b1e3288f21a7dab08ebc2fd5ff10a762
- Cited by
- 723
- References
- 149
- Citations by year
- 2026: 55 · 2025: 75 · 2024: 55 · 2023: 64 · 2022: 53 · 2021: 63 · 2020: 50 · 2019: 35 · 2018: 56 · 2017: 37 · 2016: 48 · 2015: 29 · 2014: 24 · 2013: 18 · 2012: 25
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psychedelics, mood disorders, serotonergic system, glutamatergic system, dissociative anesthetics, LSD, psilocybin, ketamine, neuroplasticity, neural circuits, psychiatric treatment
- MeSH terms
- Animals, Brain, Hallucinogens, Humans, Models, Neurological, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.